Daily Market Updates: AstraZeneca invests $2bn in Summit in cancer drug tie-up

Earnings

Home›Earnings›Previews›AstraZeneca invests $2bn in Summit in cancer drug tie-…

AstraZeneca invests $2bn in Summit in cancer drug tie-up

Reported · Written up by our desk · Previews

AstraZeneca is investing $2 billion in Summit as part of a cancer drug collaboration, according to The Guardian’s business coverage.

The report also noted that AstraZeneca shares rose 1.3% at the start of stock market trading in London, placing the company among the top gainers on the London Stock Exchange.

← Newer storySpain inflation rises to 4.9% in September, near five-year high Older story →Three Hong Kong IPO debuts open below offer prices

More like this

EarningsMicron is set to report earnings after the bell Wednesday

EarningsHarley-Davidson insider buying draws attention to turnaround outlook

EarningsMicron faces scrutiny ahead of its earnings report

EarningsAkamai lines up $11.6B Anthropic cloud deal and $5.5B capex

EarningsThe Nasdaq nears its all-time high, highlighting tech and semiconductor ETFs

Sources

Guardian BusinessAnthropic warns of ‘existential risks to humanity’ from AI; AstraZeneca makes $2bn cancer drug tie-up – business live

Guardian EconomicsAnthropic warns of ‘existential risks to humanity’ from AI; AstraZeneca makes $2bn cancer drug tie-up – business live

Earnings

AstraZeneca invests $2bn in Summit in cancer drug tie-up

More like this

Sources

Get the close, explained.